Ann: Binding Term Sheet to Immediately Expand into Latin America, page-34

In all honesty, the only deal that failed was VC and it was not MXC that failed to hold up their end of their agreement. CannaGlobal deal has been very positive for us. Would have taken us years to get it to the point where it generated the revenue we received in a short time from CannaGlobal. We continue to benefit from its growth without having to manage it. We have been doing an exceptional job with our Pharma side. With Malta on the go, prescriptions growing quickly, sales in 3 continents, it won't be long before we are cashflow positive. And this all before we have even received full marketing authorisation for our products. This is why you invest in this end of the market and it is not a quick jump with pharma companies, it is a long term hold. The current SP is more to do with the industry than MXC directly. Rerate will come.